At a meeting hosted by the Partners HealthCare Center for Personalized Genetic Medicine last month, the events leading up to the re-labeling for colorectal cancer drugs Vectibix and Erbitux sparked discussion among participants about what Amgen and Bristol-Myers Squibb/ImClone knew about the drugs and when.
The Berlin-based company is planning to market the test in Germany, Switzerland, and Austria. Epigenomics will partner with distributors Abbott Molecular and Quest Diagnostics to launch the test in other European countries, as well as the US.
OSU Medical Center will enroll patients who agree to join Coriell's personalized medicine project under the guidance of their primary care physician. The partners will study the impact of using genomic information in treating chronic conditions.
Qiagen said that the acquisition, along with the fact that it has more than 15 companion diagnostic collaborations with pharma companies, provides it with a leading position in the personalized healthcare market.
In an interview with Pharmacogenomics Reporter this week, Hakan Sakul provided a snapshot of Pfizer's efforts in personalized medicine, the company's stance on regulatory issues, and its overall focus on "omics"-guided medicine.
The results from the Australian study may have implications for US consumers, since similar to Australia, US law bars health insurers from discriminating based on genetic information, but not companies providing life and disability insurance.
Rady's Children Hospital and San Diego County are teaming up to test pediatric patients and their families for COVID-19 to gauge the spread of the virus locally, according to the San Diego Union-Tribune.